CoChat

Drug Design—Past, Present, Future

Open access
Doytchinova, Irini · 2022 · Molecules
Cited by 119

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Drug design is a complex pharmaceutical science with a long history. Many achievements have been made in the field of drug design since the end of 19th century, when Emil Fisher suggested that the drug–receptor interaction resembles the key and lock interplay. Gradually, drug design has been transformed into a coherent and well-organized science with a solid theoretical background and practical applications. Now, drug design is the most advanced approach for drug discovery. It utilizes the innovations in science and technology and includes them in its wide-ranging arsenal of methods and tools in order to achieve the main goal: discovery of effective, specific, non-toxic, safe and well-tolerated drugs. Drug design is one of the most intensively developing modern sciences and its progress is accelerated by the implication of artificial intelligence. The present review aims to capture some of the most important milestones in the development of drug design, to outline some of the most used current methods and to sketch the future perspective according to the author’s point of view. Without pretending to cover fully the wide range of drug design topics, the review introduces the reader to the content of Molecules’ Special Issue “Drug Design—Science and Practice”.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules27051496

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 39

  1. Young, D.C. (2009). Properties that make a molecule a good drug. Computational Drug Design, John Wiley & Sons, Inc. · doi:10.1002/9780470451854.ch2
  2. Rowland, M., and Tozer, T.N. (2011). Fundamental concepts and terminology. Clinical Pharmacokinetics and Pharmacodynamics, Lippincott Williams & Wilkins. [4th ed.].
  3. Sinha, S., and Vohora, D. (2018). Drug discovery and development: An overview. Pharmaceutical Medicine and Translational Clinical Research, Elsevier Inc. · DOI
  4. Doytchinova, 2018, Novel hits for acetylcholinesterase inhibition derived by docking-based screening on ZINC database, J. Enzym. Inhib. Med. Chem., 33, 768, 10.1080/14756366.2018.1458031 · DOI
  5. Ban, 2006, The role of serendipity in drug discovery, Dialogues Clin. Neurosci., 8, 335, 10.31887/DCNS.2006.8.3/tban · DOI · Paper page
  6. Cheng, 2013, Hartmann Stahelin (1925–2011) and the contested history of cyclosporin A, Clin. Transplant., 27, 326, 10.1111/ctr.12072 · DOI
  7. Guo, 2017, The modification of natural products for medical use, Acta Pharm. Sin. B, 7, 119, 10.1016/j.apsb.2016.06.003 · DOI · Paper page
  8. Montinari, 2019, The first 3500 years of aspirin history from its roots—A concise summary, Vascul. Pharmacol., 113, 1, 10.1016/j.vph.2018.10.008 · DOI · Paper page
  9. Roberts, 1984, Clinical pharmacokinetics of ranitidine, Clin. Pharmacokinet., 9, 211, 10.2165/00003088-198409030-00003 · doi:10.2165/00003088-198409030-00003
  10. Meier, 1982, Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents, Am. Heart J., 104, 364, 10.1016/0002-8703(82)90127-2 · DOI
  11. Butkiewicz, 2017, High-throughput screening assay datasets from the PubChem database, Chem. Inform., 3, 1, 10.21767/2470-6973.100022 · DOI
  12. Smith, 2002, Screening for drug discovery: The leading question, Nature, 418, 453
  13. Bentley, 2009, Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence beta-lactams), J. Ind. Microbiol. Biotechnol., 36, 775, 10.1007/s10295-009-0553-8 · DOI
  14. Wall, 1995, Camptothecin and taxol: Discovery to clinic—Thirteenth Bruce F. Cain Memorial Award Lecture, Cancer Res., 55, 753
  15. Wilson, 2011, Integrating structure-based and ligand-based approaches for computational drug design, Future Med. Chem., 3, 735, 10.4155/fmc.11.18 · DOI · Paper page
  16. Berman, 2007, The worldwide Protein Data Bank (wwPDB): Ensuring a single, uniform archive of PDB data, Nucleic Acids Res., 35, D301, 10.1093/nar/gkl971 · DOI · Paper page
  17. Novoa, 2021, A review on machine learning approaches and trends in drug discovery, Comput. Struct. Biotechnol. J., 19, 4538, 10.1016/j.csbj.2021.08.011 · DOI · Paper page
  18. Hansch, 1964, The use of substitutent constants in the analysis of the structure-activity relationship in penicillin derivatives, J. Med. Chem., 7, 691, 10.1021/jm00336a001 · DOI
  19. Martin, 2011, In tribute to Corwin Hansch, father of QSAR, J. Comput. Aided Mol. Des., 25, 491, 10.1007/s10822-011-9449-6 · doi:10.1007/s10822-011-9449-6
  20. Wold, 1983, Multivariate quantitative structure-activity relationships (QSAR): Conditions for their applicability, J. Chem. Inf. Comput. Sci., 23, 6, 10.1021/ci00037a002 · DOI · Paper page
  21. Wold, 1987, Multiway principal components and PLS-analysis, J. Chemometr., 1, 41, 10.1002/cem.1180010107 · DOI · Paper page
  22. Xu, 2002, Chemoinformatics and drug discovery, Molecules, 7, 566, 10.3390/70800566 · DOI · Paper page
  23. Mitchell, 2014, Machine learning methods in chemoinformatics, Wiley Interdiscip. Rev. Comput. Mol. Sci., 4, 468, 10.1002/wcms.1183 · DOI · Paper page
  24. Hessler, G., and Baringhaus, K.-H. (2018). Artificial Intelligence in Drug Design. Molecules, 23. · DOI · Paper page
  25. Duvaud, 2021, Expasy, the Swiss Bioinformatics Resource Portal, as designed by its users, Nucleic Acids Res., 49, W216, 10.1093/nar/gkab225 · DOI · Paper page
  26. Bragina, M.E., Daina, A., Perez, M.A.S., Michielin, O., and Zoete, V. (2022). SwissSimilarity 2021 web tool: Novel chemical libraries and additional methods for an enhanced ligand-based virtual screening experience. Int. J. Mol. Sci., 23. · DOI
  27. Cuizzo, 2022, SwissBioisostere 2021: Updated structural, bioactivity and physicochemical data delivered by a reshaped web interface, Nucleic Acids Res., 50, D1382, 10.1093/nar/gkab1047 · DOI
  28. Daina, 2019, SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules, Nucleic Acids Res., 47, W357, 10.1093/nar/gkz382 · DOI · Paper page
  29. Klucznik, 2018, Efficient syntheses of diverse, medicinally relevant targets planned by computer and executed in the laboratory, Chem, 4, 522, 10.1016/j.chempr.2018.02.002 · DOI · Paper page
  30. MacKinnon, 2021, Proteome-scale drug-target interaction predictions: Approaches and applications, Curr. Protoc., 1, e302, 10.1002/cpz1.302 · DOI
  31. Zhong, 2018, Artificial intelligence in drug design, Sci. China Life Sci., 61, 1191, 10.1007/s11427-018-9342-2 · DOI · Paper page
  32. Grisoni, 2021, Artificial intelligence in drug discovery: Recent advances and future perspectives, Expert Opin. Drug Discov., 16, 949, 10.1080/17460441.2021.1909567 · DOI · Paper page
  33. Cavasotto, 2021, Artificial intelligence in the early stages of drug discovery, Arch. Biochem. Biophys., 698, 108730, 10.1016/j.abb.2020.108730 · DOI · Paper page
  34. Zimmer, 1995, Bioorganic molecular mechanics, Chem. Rev., 95, 2629, 10.1021/cr00040a002 · doi:10.1021/cr00040a002
  35. Young, D.C. (2009). Molecular Mechanics. Computational Drug Design, John Wiley & Sons, Inc. · doi:10.1002/9780470451854.ch10
  36. Ganesan, 2017, Molecular dynamics-driven drug discovery: Leaping forward with confidence, Drug Discov. Today, 22, 249, 10.1016/j.drudis.2016.11.001 · DOI · Paper page
  37. Chen, 2009, Pharmacophore-based virtual screening versus docking-based virtual screening: A benchmark comparison against eight targets, Acta Pharmacol. Sin., 30, 1694, 10.1038/aps.2009.159 · DOI
  38. Muthas, 2008, Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering, J. Mol. Graph. Model., 26, 1237, 10.1016/j.jmgm.2007.11.005 · DOI
  39. Williams, 2015, Cheaper faster drug development validated by the repositioning of drugs against neglected tropical diseases, J. R. Soc. Interface, 12, 20141289, 10.1098/rsif.2014.1289 · DOI · Paper page

Cited by

Metadata

Authors
Doytchinova, I.
Venue
Molecules
Publisher
MDPI AG
Published
2022-02-23
Volume
27
Issue
5
Pages
1496
ISSN
1420-3049 (ISSN-L)
OpenAlex
W4213438497
Cited by
119
References
18
FWCI
11.40
Type
journal article
Language
en
Open access
gold
Funders
Science and Education for Smart Growth Operational Program (BG05M2OP001‐1.001‐0003)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.